Antibody-drug conjugates in urothelial cancer

Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with check point inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.


Learn more about the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer here, presented by Asst. Prof. Shilpa Gupta.